Kodiak Sciences (KOD) stock surged nearly 40% pre-market after Phase 3 results for its eye drug Zenkuda were positive. The study met its primary endpoint, significantly improving diabetic retinopathy scores and reducing sight-threatening complications. The CEO announced plans to accelerate the regulatory submission for the multi-indication drug.